Success Metrics

Clinical Success Rate
86.1%

Based on 31 completed trials

Completion Rate
86%(31/36)
Active Trials
0(0%)
Results Posted
55%(17 trials)
Terminated
5(13%)

Phase Distribution

Ph phase_3
8
21%
Ph phase_4
10
26%
Ph not_applicable
3
8%
Ph phase_1
11
28%
Ph phase_2
6
15%

Phase Distribution

11

Early Stage

6

Mid Stage

18

Late Stage

Phase Distribution38 total trials
Phase 1Safety & dosage
11(28.9%)
Phase 2Efficacy & side effects
6(15.8%)
Phase 3Large-scale testing
8(21.1%)
Phase 4Post-market surveillance
10(26.3%)
N/ANon-phased studies
3(7.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.6%

31 of 38 finished

Non-Completion Rate

18.4%

7 ended early

Currently Active

0

trials recruiting

Total Trials

39

all time

Status Distribution
Completed(31)
Terminated(7)
Other(1)

Detailed Status

Completed31
Terminated5
Withdrawn2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
39
Active
0
Success Rate
86.1%
Most Advanced
Phase 4

Trials by Phase

Phase 111 (28.9%)
Phase 26 (15.8%)
Phase 38 (21.1%)
Phase 410 (26.3%)
N/A3 (7.9%)

Trials by Status

terminated513%
completed3179%
unknown13%
withdrawn25%

Recent Activity

Clinical Trials (39)

Showing 20 of 39 trialsScroll for more
NCT04681105Phase 1

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Completed
NCT03368664Phase 3

A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT

Terminated
NCT04862585Phase 2

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Completed
NCT05338502Phase 1

Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants

Completed
NCT03145012Phase 4

Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity

Completed
NCT00838526Phase 3

Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

Completed
NCT02999633Phase 2

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia

Terminated
NCT04397445Phase 1

Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration

Completed
NCT00668317Phase 3

Bronchial Hyper-responsiveness in Reflux Cough

Terminated
NCT01287520Phase 1

A Study of LY2090314 in Patients With Advanced or Metastatic Cancer

Completed
NCT01332630Phase 2

TPI 287 in Breast Cancer Metastatic to the Brain

Completed
NCT03468777Phase 1

A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Participants

Terminated
NCT02441673Phase 2

Nefopam vs Tramadol in the Prevention of Post Anaesthetic Shivering

Unknown
NCT01896557Phase 4

Ranitidin Versus Omeprazole in Patients Taking Clopidogrel

Completed
NCT01539655Phase 1

Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib

Completed
NCT02441894Phase 4

Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer

Completed
NCT01392755Phase 1

A Study to Evaluate The Effects of Two Different Meal Types, Omeprazole And Ranitidine On Danoprevir Pharmacokinetics When Coadministered With Ritonavir in Healthy Volunteers

Completed
NCT02123498Phase 4

The Study of Eustachian Tube Dysfunction and Laryngopharyngeal Reflux

Withdrawn
NCT02205489Phase 4

Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA

Completed
NCT02733640Not Applicable

Does Pantoprazole Reduce the Anti-platelet Effect of Clopidogrel?

Completed

Drug Details

Intervention Type
DRUG
Total Trials
39